eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | non-alcoholic fatty liver disease |
| Comorbidity | |obesity |
| Sentences | 164 |
| PubMedID- 24339864 | Considering that we observed significant sfrp1 dependent changes in the gluconeogenic transcripts in the liver, and non-alcoholic fatty liver disease is tightly associated with obesity and hyperglycemia [31], we chose to examine the effects of a hfd in the livers of these mice. |
| PubMedID- 23653642 | nafld is strongly associated with obesity, dyslipidemia, type 2 diabetes mellitus, and cardiovascular disease. |
| PubMedID- 20355234 | In contrast to ald, nafld is commonly associated with metabolic syndrome, obesity and insulin resistance. |
| PubMedID- 26435078 | nafld is strongly associated with obesity and metabolic syndrome (mets). |
| PubMedID- 22969728 | As nafld is highly associated with obesity and diabetes, weight loss can greatly improve the health status of these patients. |
| PubMedID- 20446347 | Recent findings: obesity is associated with nonalcoholic fatty liver disease, dyslipidemia, hyperglycemia and type 2 diabetes. |
| PubMedID- 21475632 | As obesity is closely associated with nafld,11,12 it is expected that its incidence and prevalence will increase. |
| PubMedID- 23078137 | Deltal-deltas, an inverse index of nafld, was independently associated with abdominal obesity and increased triglycerides. |
| PubMedID- 22235218 | nafld is associated with central obesity, type 2 diabetes, dyslipidemia, high blood pressure, and metabolic syndrome (mets) [3]. |
| PubMedID- PMC4070608 | Both nash and nafld are associated with obesity, insulin resistance, and type 2 diabetes mellitus (t2dm). |
| PubMedID- 20644649 | Recent studies showed that nafld is closely associated with obesity, hypertension, dyslipidemia, and glucose intolerance, a cluster of metabolic disorders that is now recognized as metabolic syndrome [11], [12]. |
| PubMedID- 25921668 | Diabetes and obesity are associated with nonalcoholic fatty liver disease (nafld) and an increased incidence of hepatocellular carcinoma (hcc). |
| PubMedID- 22811894 | nafld is strongly associated with obesity, insulin resistance, hypertension, and dyslipidemia and is now regarded as the liver manifestation of the metabolic syndrome (mets) [15], a highly atherogenic condition. |
| PubMedID- 24688399 | Moreover, it is a major challenge for pharmaceutical industry to develop a combination therapy that is effective against nafld patients with obesity, insulin resistance, dyslipidemia, and oxidative stress. |
| PubMedID- 21700865 | Although nafld is strongly associated with obesity and insulin resistance, its pathogenesis remains poorly understood, and therapeutic options are limited. |
| PubMedID- 24944601 | One of the most common causes of chronic liver disease, nonalcoholic fatty liver disease (nafld), is strongly associated with obesity and dysregulated insulin action in the liver. |
| PubMedID- 24039859 | Nonalcoholic fatty liver disease (nafld) is commonly associated with obesity, the metabolic syndrome and type ii diabetes mellitus and thus its significance parallels that of the epidemic rise of these diseases in this country and much of the world [1]. |
| PubMedID- 24489859 | These findings suggest that induction of autophagy by egcg may reduce hepatosteatosis found in non-alcoholic fatty liver associated with obesity and diabetes, and may play an important role in reducing high fat diet-induced hepatosteatosis. |
| PubMedID- 25514904 | Excess accumulation of hepatic tg is a hallmark of nonalcoholic fatty liver disease, which is associated with obesity and insulin resistance. |
| PubMedID- 21042596 | nafld are frequently associated with visceral obesity, insulin resistance and metabolic syndrome [2] but predisposing and environmental factors could also be involved. |
| PubMedID- 21912450 | nafld is strongly associated with abdominal obesity, type 2 diabetes, and dyslipidemia, and most patients have evidence of insulin resistance. |
| PubMedID- 23391869 | Goals/background: nonalcoholic fatty liver disease (nafld) is associated with obesity, but it may also be present in lean individuals. |
| PubMedID- 24019613 | [4] in addition to a higher prevalence of nafld in patients with obesity, metabolic syndrome, and type 2 diabetes, it also can be induced by a variety of genetic variations. |
| PubMedID- 24638078 | non-alcoholic fatty liver disease (nafld) is closely associated with obesity and insulin resistance. |
| PubMedID- 21798002 | Consistent with the respondents comments, stickel et al, have described the increased incidence of hcc in patients with non-alcoholic fatty liver disease (nafld) which is associated with metabolic syndrome, obesity and insulin resistance [20]. |
| PubMedID- 25866590 | The development of high levels of liver fat predicts other metabolic complications, and nonalcoholic fatty liver disease is closely associated with obesity in many, but not all obese individuals [3]. |
| PubMedID- 23348961 | obesity is usually associated with nafld through an unknown mechanism. |
| PubMedID- 23756665 | obesity is strongly associated with nafld and the prevention of obesity is a major public issue. |
| PubMedID- 20197789 | Background/objectives: nonalcoholic fatty liver disease is commonly associated with obesity, insulin resistance, dyslipidemia and type 2 diabetes, and can thus be regarded as the hepatic manifestation of metabolic syndrome. |
| PubMedID- 25869913 | This article discusses the problem of severe paediatric obesity, its relationship with nafld, and the knowledge and needs regarding bariatric surgery in adolescents hospital medical center, university of cincinnati college of medicine, 3333 burnet avenue, mlc 2010, cincinnati, oh 45229, usa. |
| PubMedID- 23304111 | Simple tag accumulation in hepatocytes or steatosis is an early hallmark in nafld associated with obesity that is characterized by the multifactorial nature of the underlying pathogenic mechanisms, including the development of oxidative stress and insulin resistance [3, 52, 53], which provides the setting for further hepatic injury [54]. |
| PubMedID- 24801211 | In addition, hypoadiponentinemia was proposed to be a feature of nafld [34] and associated with obesity, hyperlipidemia and hyperglycemia, which were components of mets and characterized by ir [35]. |
| PubMedID- 24876909 | nafld often associated with overeating and obesity starts as simple steatosis and can progress to inflammation (nonalcoholic steatohepatitis, nash), fibrosis, cirrhosis, and even cancer, as similar to the progression of afld [13, 103]. |
| PubMedID- 24738043 | Risk factors for nafld, mainly obesity and diabetes, were more common in patients with cc when compared to patients with chronic hepatitis and alcoholic liver cirrhosis. |
| PubMedID- 26325428 | Nonalcoholic fatty liver disease (nafld), frequently associated with obesity and diabetes mellitus, is caused by the accumulation of excess fatty acids within liver cells. |
| PubMedID- 26052378 | nafld is strongly associated with obesity, insulin resistance, hypertension, and dyslipidaemia, and is now regarded as the liver manifestation of the metabolic syndrome. |
| PubMedID- 25644347 | Background: nonalcoholic fatty liver disease is positively associated with obesity and cardiovascular disease risk. |
| PubMedID- 24391588 | non-alcoholic fatty liver disease (nafld) is strongly associated with obesity, type 2 diabetes and dyslipidemia. |
| PubMedID- 24693952 | While nafld is closely associated with obesity, type 2 diabetes mellitus and coronary artery disease (cad), it may occur in the absence of type 2 diabetes and cad [6,7]. |
| PubMedID- 24758604 | nafld is strongly associated with obesity, insulin resistance, hypertension, and dyslipidemia, and is now regarded as the liver manifestation of the metabolic syndrome (mets). |
| PubMedID- 25623289 | nafld is closely associated with obesity, hyperlipemia and type 2 diabetes, and thus often regarded as atypical hepatic manifestation of the metabolic syndrome [3]. |
| PubMedID- 23117851 | Although nafld is usually associated with obesity, nonobese patients can also present with nafld ("lean nafld"). |
| PubMedID- 25655252 | Due to the high prevalence of obesity in subjects with nafld, obstructive sleep apnoea (osa) is very common and often unrecognised. |
| PubMedID- 23329013 | Background and aim: nonalcoholic fatty liver disease (nafld) is strongly associated with obesity, hyperlipidemia, and type 2 diabetes mellitus. |
| PubMedID- 26089873 | nafld, which is associated with obesity and metabolic syndrome, is an increasing concern worldwide and especially in the united states. |
| PubMedID- 23170042 | (24,25) the development of nafld is closely associated with obesity and type 2 diabetes. |
| PubMedID- 21042270 | nafld is strongly associated with abdominal obesity, type 2 diabetes, and dyslipidemia, and most patients have evidence of insulin resistance. |
| PubMedID- 22372457 | nafld is associated with obesity, diabetes, and insulin resistance, and is considered to be the liver manifestation of the metabolic syndrome. |
| PubMedID- 25951129 | nafld is linked with obesity, type-2 diabetes and metabolic syndrome, and is now the most prevalent liver disorder in western countries. |
| PubMedID- 22519397 | nonalcoholic fatty liver disease is associated with obesity and contributes to insulin resistance, and metformin is used to treat individuals with these conditions. |